

FEB - 2 2011

APPENDIX A: 510(k) SUMMARY

Sponsor/Submitter: Arstasis, Inc.
1021 Howard Avenue, Suite C
San Carlos, CA 94070

Contact Person: Debra Cogan
Director, Regulatory & Clinical Affairs
Phone: (650) 508-1549 x273
Fax: (650) 594-4326

Date of Submission: October 22, 2010

Device Trade Name: Arstasis^{one} Latchwire Access System

Common Name: Catheter Introducer

Device Classification: Class II

Regulation Number: 21 CFR 870.1340

Classification Name: Catheter Introducer

Product Code: DYB

Predicate Device: Arstasis^{one} Access System (K102728)

Device Description: Arstasis^{one} is a device that is comprised of a latchwire, anchor mechanism, shaft and handle with control features.

Indications for Use: The System is intended to provide access for the percutaneous introduction of devices into the peripheral vasculature and to promote hemostasis at the arteriotomy site as an adjunct to manual compression. The System is indicated for use in patients undergoing diagnostic femoral artery catheterization procedures using 5F or 6F introducer sheaths.

Technological Characteristics: Arstasis^{one} Latchwire device is designed to create a shallow access path through the arterial wall for the guidewire to enter the vessel lumen.

Performance Data: Arstasis^{one} met all performance testing acceptance criteria.

Summary of Substantial Equivalence: Bench testing was performed on the Latchwire Device following sterilization of test units. Parameters tested include functionality testing, deployment forces, corrosion resistance, compression and torque loading, flexibility and tensile strength. Tensile testing for the 19 gauge Access Needle was performed following gamma radiation.

Additional prior testing included biocompatibility testing pursuant to ISO-10993-1, Biological Evaluation of Medical Devices Part 1: Evaluation and Testing (1995), preliminary animal studies (non-GLP) and cadaver assessments, as well as clinical investigations.¹ Multiple clinical evaluations were conducted. The short term safety and clinical performance of the device were established. The long term safety, as well as the ability to access and re-access, was retrospectively studied in a smaller cohort of patients.

In summary, the cumulative data provided herein demonstrates that the Arstasis[™] Latchwire Access System is substantially equivalent to its predicate in providing access to the arterial lumen and facilitating the introduction and placement of devices into the peripheral vasculature and achievement of hemostasis.

¹ The preliminary Animal Studies and Cadaver Assessments were conducted using prototypes of a similar design and configuration.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room -WO66-G609
Silver Spring, MD 20993-0002

Arstasis, Inc.
c/o Debra Cogan
Director, Regulatory & Clinical Affairs
740 Bay Rd
Redwood City, CA 94063

FEB - 2 2011

Re: K103143

Trade/Device Name: Arstasis^{onc} Latchwire Access System
Regulation Number: 21 CFR 870.1340
Regulation Name: Catheter introducer
Regulatory Class: Class II (two)
Product Code: DYB
Dated: January 25, 2011
Received: January 26, 2011

Dear Ms. Cogan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

APPENDIX B: INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K103143

Trade Name: Arstasis^{one} Latchwire Access System

Common Name: Catheter Introducer

Indications For Use: The System is intended to provide access for the percutaneous introduction of devices into the peripheral vasculature and to promote hemostasis at the arteriotomy site as an adjunct to manual compression. The System is indicated for use in patients undergoing diagnostic femoral artery catheterization procedures using 5F or 6F introducer sheaths.


Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)
Division of Cardiovascular Devices
510(k) Number K103143

Page ___ of ___

(Posted November 13, 2003)